{"id":744952,"date":"2014-07-24T07:30:00","date_gmt":"2014-07-24T07:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-3-study-of-letermovir-an-investigational-antiviral-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients\/"},"modified":"2023-03-22T00:04:52","modified_gmt":"2023-03-22T04:04:52","slug":"merck-initiates-phase-3-study-of-letermovir-an-investigational-antiviral-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-3-study-of-letermovir-an-investigational-antiviral-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients\/","title":{"rendered":"Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the first patient has been enrolled in a global<br \/>\n      Phase 3 clinical study of letermovir (MK-8228), an investigational<br \/>\n      antiviral agent. The multicenter, randomized, placebo-controlled study<br \/>\n      will evaluate the efficacy and safety of letermovir for the prevention<br \/>\n      of clinically-significant cytomegalovirus (CMV) infection in adult (18<br \/>\n      years and older) CMV-seropositive recipients of allogeneic hematopoietic<br \/>\n      stem cell transplants.\n    <\/p>\n<p>\n      \u201cThere remains a need for additional therapeutic options in the<br \/>\n      prevention of CMV infection in high-risk patients,\u201d said Dr. Michele<br \/>\n      Trucksis, executive director, Infectious Diseases, Merck Research<br \/>\n      Laboratories. \u201cMerck is pleased to initiate this global Phase 3 study<br \/>\n      with letermovir.\u201d\n    <\/p>\n<p>\n      \u201cThis study marks a very important step in the development of letermovir<br \/>\n      and for AiCuris as licensor of this compound,\u201d said Prof. Helga<br \/>\n      R\u00fcbsamen-Schaeff, CEO of AiCuris. \u201cWe are very excited to have reached<br \/>\n      this stage and look forward to the results.\u201d\n    <\/p>\n<p>\n      In the study, letermovir will be administered once daily, either as an<br \/>\n      oral tablet or IV formulation, for 14 weeks after transplant. The dose<br \/>\n      will be 240 mg once daily for participants receiving concomitant<br \/>\n      cyclosporin A and 480 mg once daily for participants not receiving<br \/>\n      cyclosporin A. The primary outcome measure of the study will be the<br \/>\n      percentage of participants with clinically-significant CMV infection<br \/>\n      through 24 weeks after transplant who were administered letermovir<br \/>\n      compared to placebo.\n    <\/p>\n<p>\n      Merck expects approximately 540 patients will be enrolled in the study<br \/>\n      at more than 70 centers in 20 countries, including the United States.<br \/>\n      The estimated study completion date is July 2017.\n    <\/p>\n<p>\n      To learn more about the study, please contact Merck at 1-888-577-8839 or<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinical-trials&#038;esheet=50911426&#038;newsitemid=20140724005207&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated%2Fclinical-trials&#038;index=1&#038;md5=c5f5f8a8efa52914b4b4223eebced46d\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinical-trials<\/a>.<br \/>\n      Additional details can also be found online at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02137772&#038;esheet=50911426&#038;newsitemid=20140724005207&#038;lan=en-US&#038;anchor=www.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02137772&#038;index=2&#038;md5=c183d7169e69e157743efc98cb414382\" rel=\"nofollow\">www.clinicaltrials.gov\/ct2\/show\/NCT02137772<\/a>.\n    <\/p>\n<p>\n      <b>About letermovir<\/b>\n    <\/p>\n<p>\n      Letermovir is an investigational once-daily antiviral agent under<br \/>\n      development for the prevention of human CMV infection. It is derived<br \/>\n      from a novel chemical class (quinazolines) and is designed to inhibit<br \/>\n      the human CMV viral terminase. Letermovir has been granted Orphan<br \/>\n      Product Designation by the European Medicines Agency (EMA) and the U.S.<br \/>\n      Food and Drug Administration (FDA) for the prevention of CMV viremia and<br \/>\n      disease in at-risk populations and also has been granted Fast Track<br \/>\n      Status by the FDA.\n    <\/p>\n<p>\n      Under an agreement signed in 2012, Merck (through a subsidiary)<br \/>\n      purchased worldwide rights to develop and commercialize letermovir from<br \/>\n      AiCuris GmbH &#038; Co KG (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.aicuris.com&#038;esheet=50911426&#038;newsitemid=20140724005207&#038;lan=en-US&#038;anchor=www.aicuris.com&#038;index=3&#038;md5=6e2c51e6735ece5390e2f45bf069e59a\" rel=\"nofollow\">www.aicuris.com<\/a>).\n    <\/p>\n<p>\n      <b>About CMV<\/b>\n    <\/p>\n<p>\n      CMV is widely spread in the human population and can cause severe,<br \/>\n      life-threatening infections in cases of immune incompetency or immune<br \/>\n      deficiency, such as, for example, in transplant recipients. CMV<br \/>\n      infection is characterized by fever, leukopenia (very low white blood<br \/>\n      cell count) and thrombocytopenia (very low platelet numbers) with or<br \/>\n      without specific organ dysfunction. Two main strategies to prevent CMV<br \/>\n      infection in transplant recipients at risk have been adopted: anti-CMV<br \/>\n      drug prophylaxis or surveillance and pre-emptive treatment of transplant<br \/>\n      recipients with evidence of CMV viremia.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside of the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50911426&#038;newsitemid=20140724005207&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=4&#038;md5=cbbdc7e88bb7a15fb0e89bb1a7629581\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.twitter%2FMerck&#038;esheet=50911426&#038;newsitemid=20140724005207&#038;lan=en-US&#038;anchor=Twitter&#038;index=5&#038;md5=52a176c2d9bc84079904eb5e56a690c3\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&#038;esheet=50911426&#038;newsitemid=20140724005207&#038;lan=en-US&#038;anchor=Facebook&#038;index=6&#038;md5=5399aa2edefe81b7a1847e87a93e0b5e\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2FMerck&#038;esheet=50911426&#038;newsitemid=20140724005207&#038;lan=en-US&#038;anchor=YouTube&#038;index=7&#038;md5=cc14bb1aad6349ac475ac7e85d7f56a0\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50911426&#038;newsitemid=20140724005207&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=8&#038;md5=077f99de5f5248be6c3a5e476b1425d4\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20140724005207r1&#038;sid=hq1sf1&#038;distro=nx&#038;lang=en\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pam Eisele, 267-305-3558<br \/>or<br \/>Robert        Consalvo, 908-423-6595<br \/>or<br \/>Investor:<br \/>Joseph Romanelli,        908-423-5185<br \/>or<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in a global Phase 3 clinical study of letermovir (MK-8228), an investigational antiviral agent. The multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of letermovir for the prevention of clinically-significant cytomegalovirus (CMV) infection in adult (18 years and older) CMV-seropositive recipients of allogeneic hematopoietic stem cell transplants. \u201cThere remains a need for additional therapeutic options in the prevention of CMV infection in high-risk patients,\u201d said Dr. Michele Trucksis, executive director, Infectious Diseases, Merck Research Laboratories. \u201cMerck is pleased to initiate this global Phase 3 study with letermovir.\u201d \u201cThis study marks a very important step in the development of letermovir and for AiCuris as licensor of this compound,\u201d said Prof. Helga R\u00fcbsamen-Schaeff, CEO of AiCuris. \u201cWe are very excited to<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-744952","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-3-study-of-letermovir-an-investigational-antiviral-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in a global Phase 3 clinical study of letermovir (MK-8228), an investigational antiviral agent. The multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of letermovir for the prevention of clinically-significant cytomegalovirus (CMV) infection in adult (18 years and older) CMV-seropositive recipients of allogeneic hematopoietic stem cell transplants. \u201cThere remains a need for additional therapeutic options in the prevention of CMV infection in high-risk patients,\u201d said Dr. Michele Trucksis, executive director, Infectious Diseases, Merck Research Laboratories. \u201cMerck is pleased to initiate this global Phase 3 study with letermovir.\u201d \u201cThis study marks a very important step in the development of letermovir and for AiCuris as licensor of this compound,\u201d said Prof. Helga R\u00fcbsamen-Schaeff, CEO of AiCuris. \u201cWe are very excited to\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-3-study-of-letermovir-an-investigational-antiviral-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:52+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140724005207r1&sid=hq1sf1&distro=nx&lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-initiates-phase-3-study-of-letermovir-an-investigational-antiviral-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-initiates-phase-3-study-of-letermovir-an-investigational-antiviral-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients\\\/\",\"name\":\"Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-initiates-phase-3-study-of-letermovir-an-investigational-antiviral-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-initiates-phase-3-study-of-letermovir-an-investigational-antiviral-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140724005207r1&sid=hq1sf1&distro=nx&lang=en\",\"datePublished\":\"2014-07-24T07:30:00+00:00\",\"dateModified\":\"2023-03-22T04:04:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-initiates-phase-3-study-of-letermovir-an-investigational-antiviral-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-initiates-phase-3-study-of-letermovir-an-investigational-antiviral-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-initiates-phase-3-study-of-letermovir-an-investigational-antiviral-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140724005207r1&sid=hq1sf1&distro=nx&lang=en\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140724005207r1&sid=hq1sf1&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-initiates-phase-3-study-of-letermovir-an-investigational-antiviral-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-3-study-of-letermovir-an-investigational-antiviral-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients\/","og_locale":"en_US","og_type":"article","og_title":"Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in a global Phase 3 clinical study of letermovir (MK-8228), an investigational antiviral agent. The multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of letermovir for the prevention of clinically-significant cytomegalovirus (CMV) infection in adult (18 years and older) CMV-seropositive recipients of allogeneic hematopoietic stem cell transplants. \u201cThere remains a need for additional therapeutic options in the prevention of CMV infection in high-risk patients,\u201d said Dr. Michele Trucksis, executive director, Infectious Diseases, Merck Research Laboratories. \u201cMerck is pleased to initiate this global Phase 3 study with letermovir.\u201d \u201cThis study marks a very important step in the development of letermovir and for AiCuris as licensor of this compound,\u201d said Prof. Helga R\u00fcbsamen-Schaeff, CEO of AiCuris. \u201cWe are very excited to","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-3-study-of-letermovir-an-investigational-antiviral-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:52+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140724005207r1&sid=hq1sf1&distro=nx&lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-3-study-of-letermovir-an-investigational-antiviral-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-3-study-of-letermovir-an-investigational-antiviral-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients\/","name":"Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-3-study-of-letermovir-an-investigational-antiviral-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-3-study-of-letermovir-an-investigational-antiviral-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140724005207r1&sid=hq1sf1&distro=nx&lang=en","datePublished":"2014-07-24T07:30:00+00:00","dateModified":"2023-03-22T04:04:52+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-3-study-of-letermovir-an-investigational-antiviral-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-3-study-of-letermovir-an-investigational-antiviral-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-3-study-of-letermovir-an-investigational-antiviral-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140724005207r1&sid=hq1sf1&distro=nx&lang=en","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140724005207r1&sid=hq1sf1&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-initiates-phase-3-study-of-letermovir-an-investigational-antiviral-for-prevention-of-cytomegalovirus-cmv-infection-in-high-risk-bone-marrow-transplant-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"4f76f93d-7874-41b6-ba7c-c9adc76033ad","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744952\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744952"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}